NPJ Vaccines最新文献_第2页

A19Δbpe275 emerges as a safer live attenuated vaccine candidate. A19Δbpe275作为一种更安全的减毒活疫苗候选出现。

IF 7.2 1区医学

NPJ Vaccines Pub Date : 2026-07-16 DOI: 10.1038/s41541-026-01522-9

Enhui Dai, Dongjie Sun, Yifan Wu, Mengtao Zhang, Yanxiao Zhao, Shijin Jiang, Jiabo Ding

{"title":"A19Δbpe275 emerges as a safer live attenuated vaccine candidate.","authors":"Enhui Dai, Dongjie Sun, Yifan Wu, Mengtao Zhang, Yanxiao Zhao, Shijin Jiang, Jiabo Ding","doi":"10.1038/s41541-026-01522-9","DOIUrl":"https://doi.org/10.1038/s41541-026-01522-9","url":null,"abstract":"Brucellosis remains a major global challenge to both animal production and public health. Brucella abortus A19, are limited in their application due to residual virulence and interference with serodiagnosis. The intracellular survival and immune evasion of Brucella critically depend on effector proteins delivered by the Type IV Secretion System (T4SS), yet the functions of many of these effectors remain poorly defined. In this study, we constructed a markerless deletion mutant A19Δbpe275, and comprehensively evaluated its phenotype, virulence, and vaccine potential. The A19Δbpe275 mutant retained smooth lipopolysaccharide (LPS) structure, in vitro growth kinetics, and genetic stability, but exhibited significantly impaired long-term intracellular survival in macrophages. In murine infection models, A19Δbpe275 displayed markedly attenuated virulence, characterized by consistently lower splenic bacterial loads, milder histopathological lesions, and accelerated clearance. Immunologically, infection with A19Δbpe275 was associated with a robust and sustained immune profile characterized by elevated Th1-associated cytokines. A19Δbpe275 conferred comparable protective efficacy an improved safety profile in the non-pregnant murine model against challenge with the virulent B. abortus 2308 and demonstrated cross-protection against B. melitensis 16 M. Collectively, by achieving an optimal balance between attenuated virulence and preserved immunogenicity, A19Δbpe275 emerges as a promising candidate for next-generation live attenuated brucellosis vaccines.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148472102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety and immunogenicity testing of a melioidosis subunit vaccine candidate in cynomolgus macaques. 食蟹猴类鼻疽亚单位候选疫苗的安全性和免疫原性试验。

IF 7.2 1区医学

NPJ Vaccines Pub Date : 2026-07-14 DOI: 10.1038/s41541-026-01526-5

Sineenart Sengyee, Caitlyn E Orne, Sarah B Weiby, Lindsey K Schmidt, Federico Urbano-Munoz, Jiri Vlach, Christian Heiss, Parastoo Azadi, Narisara Chantratita, Mary N Burtnick, Paul J Brett

{"title":"Safety and immunogenicity testing of a melioidosis subunit vaccine candidate in cynomolgus macaques.","authors":"Sineenart Sengyee, Caitlyn E Orne, Sarah B Weiby, Lindsey K Schmidt, Federico Urbano-Munoz, Jiri Vlach, Christian Heiss, Parastoo Azadi, Narisara Chantratita, Mary N Burtnick, Paul J Brett","doi":"10.1038/s41541-026-01526-5","DOIUrl":"https://doi.org/10.1038/s41541-026-01526-5","url":null,"abstract":"Burkholderia pseudomallei, the etiologic agent of melioidosis, is a Gram-negative bacterial pathogen that causes severe disease in humans and animals. In this study, we evaluated the safety and immunogenicity of our lead melioidosis subunit vaccine candidate in cynomolgus macaques. To accomplish this, the 6-deoxyheptan capsular polysaccharide (CPS) from Burkholderia thailandensis E555 was purified using a phenol-free extraction process and then conjugated to CRM197 to generate CPS-CRM197. Highly purified, His-tagless B. pseudomallei Hcp1 (Hcp1-TL) was also produced. Animals immunized with CPS-CRM197 combined with Hcp1-TL and adjuvanted with Alhydrogel plus CpG DNA (ODN 2006) developed robust CPS-specific IgG and opsonizing antibody responses, alongside strong Hcp1-specific IgG and measurable IFN-γ-secreting T-cell responses. Importantly, the vaccine formulations tested were well tolerated, with no adverse events after three doses. Collectively, these studies establish good manufacturing practices-compatible processes for our vaccine antigens and demonstrate the safety and immunogenicity of the subunit vaccine in non-human primates, supporting continued advancement towards a human clinical trial.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148448394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optimization of heroin conjugate vaccine performance in rodent models. 海洛因结合疫苗在啮齿动物模型上的性能优化。

IF 7.2 1区医学

NPJ Vaccines Pub Date : 2026-07-14 DOI: 10.1038/s41541-026-01517-6

Essie Komla, Connor Whalen, Oscar B Torres, Agnieszka Sulima, Arthur E Jacobson, Kenner C Rice, Gary R Matyas

{"title":"Optimization of heroin conjugate vaccine performance in rodent models.","authors":"Essie Komla, Connor Whalen, Oscar B Torres, Agnieszka Sulima, Arthur E Jacobson, Kenner C Rice, Gary R Matyas","doi":"10.1038/s41541-026-01517-6","DOIUrl":"https://doi.org/10.1038/s41541-026-01517-6","url":null,"abstract":"Opioid use disorder (OUD) remains a global public health concern, exerting a significant economic burden on societies worldwide. To combat the rise of substance use disorder, a complementary vaccine-based intervention was developed to support and strengthen the existing treatment modalities. Hapten-protein conjugate vaccines are employed as a promising novel strategy for neutralizing nonimmunogenic small-molecule drugs such as opioids by eliciting drug-specific antibodies that sequester opioids in circulation before reaching the brain. In this study, multiple parameters to optimize the efficacy of the TT-6-AmHap heroin conjugate vaccine were investigated in mice and rats, focusing on dose optimization, hapten density, booster timing, and cross-reactivity with other prescription opioids. Binding antibody responses were quantified, and vaccine efficacy was assessed using nociceptive assays following a drug challenge. Immunization with TT-6-AmHap vaccine in combination with adjuvants ALF43 and Alhydrogel® (ALFA), demonstrated a robust in-vivo efficacy across multiple opioid challenges including heroin, hydrocodone, and hydromorphone. Both antibody titers to 6-AmHap and protective efficacy were maintained following repeated heroin challenges up to 54 weeks. Notably, these repeat heroin challenges did not induce any measurable decline in antibody titers. Further characterization of the vaccine responses indicated a strong correlation between hapten density on the carrier protein and both binding antibody titers and overall vaccine efficacy. These findings support the continued development of hapten-based conjugate vaccines for OUD and demonstrate that an optimized vaccine can provide long-lasting protection against the antinociceptive effects of opioids in animals, laying the groundwork for future translational studies.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148448398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intranasal and intramuscular H5-Matrix-M nanoparticle vaccines protects against highly pathogenic H5N1 influenza virus in mice. 鼻腔和肌肉注射h5 -基质- m纳米颗粒疫苗可预防小鼠高致病性H5N1流感病毒。

IF 7.2 1区医学

NPJ Vaccines Pub Date : 2026-07-10 DOI: 10.1038/s41541-026-01523-8

Kelly Pyles, Tamarand L Darling, Lin-Chen Huang, Mimi Guebre-Xabier, Melinda Hersey, Ann M Greene, Nita Patel, Gale Smith, Adrianus C M Boon

{"title":"Intranasal and intramuscular H5-Matrix-M nanoparticle vaccines protects against highly pathogenic H5N1 influenza virus in mice.","authors":"Kelly Pyles, Tamarand L Darling, Lin-Chen Huang, Mimi Guebre-Xabier, Melinda Hersey, Ann M Greene, Nita Patel, Gale Smith, Adrianus C M Boon","doi":"10.1038/s41541-026-01523-8","DOIUrl":"https://doi.org/10.1038/s41541-026-01523-8","url":null,"abstract":"The emergence of clade 2.3.4.4b highly pathogenic H5N1 influenza virus in dairy cows and transmission to humans has heightened public health concerns. In this work, we characterized the immunogenicity and efficacy of a Matrix-M®-adjuvanted nanoparticle protein vaccine containing recombinant H5 HA of A/American wigeon/South Carolina/22/000345-001/2021 virus (clade 2.3.4.4b, H5-MNP). In naïve mice, intranasal or intramuscular vaccination with H5-MNP induced robust H5 binding and virus neutralizing antibody responses and protected against a lethal H5N1 challenge (A/Michigan/90/2024, clade 2.3.4.4b). In mice primed with seasonal influenza vaccine, one dose of H5-MNP vaccine provided similar levels of protection, with fewer breakthrough infections detected in the upper airways of mice that received the H5-MNP intranasally compared to those that were immunized intramuscularly. This novel H5-MNP vaccine technology could potentially induce protective immunity against pandemic influenza viruses in individuals with pre-existing seasonal influenza HA immunity.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148423012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effect of a spore-based Mannheimia haemolytica vaccine on immune responses and respiratory microbiota in sheep. 孢子型溶血性曼海姆病疫苗对绵羊免疫反应和呼吸道微生物群的影响。

IF 7.2 1区医学

NPJ Vaccines Pub Date : 2026-07-10 DOI: 10.1038/s41541-026-01415-x

Muhammed Salah Uddin, José Ortiz Guluarte, Timothy D Schwinghamer, Daniel R Barreda, Tim A McAllister, Le Luo Guan, Trevor W Alexander

{"title":"Effect of a spore-based Mannheimia haemolytica vaccine on immune responses and respiratory microbiota in sheep.","authors":"Muhammed Salah Uddin, José Ortiz Guluarte, Timothy D Schwinghamer, Daniel R Barreda, Tim A McAllister, Le Luo Guan, Trevor W Alexander","doi":"10.1038/s41541-026-01415-x","DOIUrl":"10.1038/s41541-026-01415-x","url":null,"abstract":"Mannheimia haemolytica is an opportunistic pathogen associated with respiratory disease in ruminants. Current vaccines provide incomplete protection, highlighting the need for improved immunization strategies. In this study, a mucosal vaccine was developed using Bacillus subtilis spores as an adjuvant and evaluated for its effects on immune responses and respiratory microbiota in sheep. A chimeric protein (MhCP) containing neutralizing epitopes from leukotoxin A (NLKT) and outer membrane protein PlpE was expressed and adsorbed onto spores to produce Spore-MhCP, which was administered via two mucosal routes: intranasal and intragastric. Unbound MhCP was delivered intranasally and intramuscularly, while unbound spores and saline were used as controls. Intranasal Spore-MhCP generated the strongest secretory IgA-specific responses against PlpE and NLKT in nasal swab, bronchoalveolar lavage, and fecal samples. It also elicited earlier and sustained serum IgG responses among mucosal immunization groups. Notably, intragastric vaccination also increased PlpE- and NLKT-specific antibodies in lung and fecal samples. From nasopharyngeal samples, 16S rRNA gene sequencing revealed 27 genera altered in the intranasal Spore-MhCP group, including a decrease in Mannheimia (days 14-35; p < 0.01). These findings indicate that intranasal Spore-MhCP enhances immunity and may reduce M. haemolytica proliferation in the upper respiratory tract, reducing lung infection risk.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"11 1","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13354553/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148423083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hemagglutination-inhibition and microneutralization antibody titers as mediators of protection for cell-based and recombinant influenza vaccines. 血凝抑制和微中和抗体滴度作为细胞和重组流感疫苗的保护介质。

IF 7.2 1区医学

NPJ Vaccines Pub Date : 2026-07-09 DOI: 10.1038/s41541-026-01521-w

Shuyi Zhong, Wey Wen Lim, Faith Ho, Manjusha Gaglani, Allison L Naleway, Fatimah S Dawood, Min Z Levine, Kelsey Sumner, Brendan Flannery, Benjamin J Cowling

{"title":"Hemagglutination-inhibition and microneutralization antibody titers as mediators of protection for cell-based and recombinant influenza vaccines.","authors":"Shuyi Zhong, Wey Wen Lim, Faith Ho, Manjusha Gaglani, Allison L Naleway, Fatimah S Dawood, Min Z Levine, Kelsey Sumner, Brendan Flannery, Benjamin J Cowling","doi":"10.1038/s41541-026-01521-w","DOIUrl":"https://doi.org/10.1038/s41541-026-01521-w","url":null,"abstract":"The proportion of relative influenza vaccine efficacy (rVE) mediated by post-vaccination hemagglutination inhibition (HAI) and microneutralization (MN) antibody titers has not been evaluated. We compared rVE by influenza vaccine type and HAI and MN antibody titer against symptomatic influenza A(H3N2) infection in a randomized immunogenicity trial of quadrivalent cell culture-based (ccIIV4), recombinant (RIV4), and egg-based (eIIV4) influenza vaccines in US healthcare personnel, and estimated proportions of rVE mediated by antibody titers using causal mediation analysis. Cumulative influenza A(H3N2) incidence was 3.2%, 1.3% and 1% among ccIIV, eIIV4 and RIV4 recipients, respectively. Age-adjusted rVE estimates were not statistically significant. Higher MN and HAI titers against A(H3N2) vaccine and circulating viruses explained 97.9% and 15.8%, respectively, of rVE for RIV4 compared with ccIIV4, versus 1.7% and 12.6% of rVE for eIIV4 compared with ccIIV4, indicating MN titers to be used as correlates of protection against A(H3N2) for comparisons between cell-based influenza vaccines.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148423070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Post-exposure vaccination with an adjuvanted protein subunit vaccine, but not BCG, protects mice and guinea pigs against M. tuberculosis. 暴露后接种佐剂蛋白亚单位疫苗，而不是卡介苗，可以保护小鼠和豚鼠免受结核分枝杆菌的侵害。

IF 7.2 1区医学

NPJ Vaccines Pub Date : 2026-07-08 DOI: 10.1038/s41541-026-01509-6

Joshua S Woodworth, Claus Aagaard, Francisco J Salguero, Laura Hunter, Thomas Lindenstrøm, Simon Clark, Rasmus Mortensen

{"title":"Post-exposure vaccination with an adjuvanted protein subunit vaccine, but not BCG, protects mice and guinea pigs against M. tuberculosis.","authors":"Joshua S Woodworth, Claus Aagaard, Francisco J Salguero, Laura Hunter, Thomas Lindenstrøm, Simon Clark, Rasmus Mortensen","doi":"10.1038/s41541-026-01509-6","DOIUrl":"https://doi.org/10.1038/s41541-026-01509-6","url":null,"abstract":"Tuberculosis (TB) remains a global health priority and vaccines targeting populations with prior Mycobacterium tuberculosis (Mtb) exposure are predicted to most rapidly impact epidemic control. Paradoxically, while efficacy trials are primarily targeting previously Mtb-exposed populations, preclinical testing largely relies on Mtb-naïve animal models. We introduce two post-exposure models, a murine reinfection model and a previously unreported guinea pig reactivation model, and evaluate the efficacy of the adjuvanted protein subunit vaccine H107/CAF®01 compared to Bacillus Calmette-Guérin (BCG). Consistent with clinical and human population data, we demonstrate that BCG fails to confer significant protection in these post-Mtb-exposed settings. In contrast, H107/CAF®01 imprints distinct Th17 responses and provides robust and consistent protection, reducing both the bacterial burden and infection-associated tissue pathology. These findings support the development of H107 as a vaccine candidate in previously Mtb-exposed and infected populations and underscores the importance of evaluating TB vaccines in animal models that reflect prior exposure.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148405213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A next-generation human lymphatic filariasis vaccine candidate, rBmHAXT, for clinical development. 用于临床开发的下一代人淋巴丝虫病候选疫苗rBmHAXT。

IF 7.2 1区医学

NPJ Vaccines Pub Date : 2026-07-08 DOI: 10.1038/s41541-026-01497-7

Nithila Saravanan, Sean A Gray, Jennifer Davis, Conrad M Puff-Carter, Jiho Kim, Vishal Khatri, Nikhil Chauhan, Darrick Carter, Ramaswamy Kalyanasundaram

{"title":"A next-generation human lymphatic filariasis vaccine candidate, rBmHAXT, for clinical development.","authors":"Nithila Saravanan, Sean A Gray, Jennifer Davis, Conrad M Puff-Carter, Jiho Kim, Vishal Khatri, Nikhil Chauhan, Darrick Carter, Ramaswamy Kalyanasundaram","doi":"10.1038/s41541-026-01497-7","DOIUrl":"10.1038/s41541-026-01497-7","url":null,"abstract":"This study was conducted to develop a robust, scalable manufacturing process for the candidate vaccine rBmHAXT for human lymphatic filariasis (LF). During scale-up production, rBmHAXT showed significant antigen aggregation leading to a loss of purified vaccine antigens. This project aims to create an improved formulation suitable for industrial-scale production while maintaining robust protection. We generated three variants: (1) ∆Cys, in which all cysteinyl residues were mutated to serinyl. (2) GS, which has a flexible glycine-serine linker inserted between each of the component antigens, and (3) GS/∆Cys, a third variant with a combination of both the cysteine deletion and the addition of linkers. We then evaluated the immunogenicity and efficacy of each variant in a mouse model. We demonstrated that the ΔCys mutant retained immunogenicity and vaccine efficacy of the parent tag-free rBmHAXT protein. We also performed an accelerated stability study. All preparations remained stable at 4°C, and the ΔCys variant remained stable even at 25°C throughout the study (6 weeks). The ∆Cys protein was stable with equivalent potency in mice. Therefore, ∆Cys is an optimal candidate for progression to cGMP (Current Good Manufacturing Practices) manufacturing and human clinical trials as a vaccine for lymphatic filariasis.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13499809/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148405235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world effectiveness and impact of the 4CMenB vaccine against serogroup B invasive meningococcal disease: a systematic review and meta-analysis. 4CMenB疫苗对血清B群侵袭性脑膜炎球菌病的实际有效性和影响：系统回顾和荟萃分析

IF 7.2 1区医学

NPJ Vaccines Pub Date : 2026-07-06 DOI: 10.1038/s41541-026-01511-y

Pavo Marijic, Katarzyna Jamróz-Dolińska, Wojciech Margas, Lucian Gaianu, Gaurav Mathur, Piotr Wojciechowski, Thatiana Pinto, Tia Vincent, Helen Petousis-Harris, Terry Nolan, Federico Martinón-Torres, Lee H Harrison, Zeki Kocaata

{"title":"Real-world effectiveness and impact of the 4CMenB vaccine against serogroup B invasive meningococcal disease: a systematic review and meta-analysis.","authors":"Pavo Marijic, Katarzyna Jamróz-Dolińska, Wojciech Margas, Lucian Gaianu, Gaurav Mathur, Piotr Wojciechowski, Thatiana Pinto, Tia Vincent, Helen Petousis-Harris, Terry Nolan, Federico Martinón-Torres, Lee H Harrison, Zeki Kocaata","doi":"10.1038/s41541-026-01511-y","DOIUrl":"10.1038/s41541-026-01511-y","url":null,"abstract":"4CMenB vaccine is authorized for protection against serogroup B invasive meningococcal disease (IMD). This study synthesized real-world evidence (RWE) data on effectiveness and impact of 4CMenB vaccine. A systematic search identified RWE on vaccine effectiveness (VE) and vaccine impact of 4CMenB in infants, children and adolescents. A meta-analysis was conducted of 4CMenB VE against serogroup B-IMD in infants and children. The primary meta-analysis used a random-effects model on data from five studies from five countries reporting VE in fully vaccinated infants and children, and estimated pooled VE at 79.7% (95% confidence interval 70.4, 86.1). In sensitivity analyzes, inclusion/exclusion of studies from the primary analysis did not materially change the results. Age-specific data in adolescents were summarized qualitatively. Data identified from Australia reported high effectiveness and impact in adolescents. This meta-analysis provides evidence of high 4CMenB VE against serogroup B-IMD in fully vaccinated infants and children across different geographic regions. Clinical trial registration: N/A.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13401604/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148397461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preclinical immunogenicity of the LP.8.1-adapted BNT162b2 COVID-19 vaccine. lp .8.1适应的BNT162b2 COVID-19疫苗的临床前免疫原性

IF 7.2 1区医学

NPJ Vaccines Pub Date : 2026-07-06 DOI: 10.1038/s41541-026-01515-8

Chaitanya Kurhade, Wei Chen, Weiqiang Li, Kristin R Tompkins, Lyndsey T Martinez, Swati Rajput, Emily Babiarz, Aaron Yam, Shin-Ae Lee, Shikha Shrivastava, Sarah O'Leary, Subrata Saha, Hui Yao, Li Hao, Todd Coffey, Carla Iris Cadima Couto, Alexander Muik, Raquel Munoz Moreno, Wesley Swanson, Pilar Mendoza, Uğur Şahin, Annaliesa S Anderson, Kena A Swanson, Pirada Suphaphiphat Allen, Kayvon Modjarrad

引用次数: 0